Lion TCR Pte. Ltd. is engaged in the research, development, and commercialization of engineered T cell receptor (TCR) immunotherapy products. The company specializes in developing mRNA‑encoded TCR‑T cell therapies, such as Liocyx‑M004, targeting HBV‑related hepatocellular carcinoma, and operates as a clinical‑stage biotech firm with its own GMP facilities. It was incorporated in 2015 and is based in Singapore.
Headquarters
2 Tukang Innovation Grove #09-04
Singapore; Singapore;
Postal Code: 618305
Contact Details: Purchase the Lion TCR Pte. Ltd. report to view the information.
Website: https://www.liontcr.com/
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service